Pliant Therapeutics, Inc. (PLRX) stock
Close on Nov 11, 2026Market cap $48.15MP/E –Yield 0.00%
Pliant Therapeutics, Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$66.79M. At the latest close the market valued the company at $48.15M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $48.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.33
- Dividend yield
- 0.00%
- Free cash flow yield
- -147.24%
Fundamentals
- Revenue
- $0
- Net income
- -$90.37M
- EPS, diluted
- -$1.45
- Free cash flow
- -$66.79M
- Book value per share
- $2.04
- Diluted shares
- 62M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.79
- Open
- $0.79
- Day's range
- $0.76 – $0.79
- Volume
- 270,143
- Average volume (20 days)
- 302,163
- Beta (5 years)
- 1.02
- 52-week range
- $0.76 – $1.81
- RSI (14 days)
- 28.5
- Volatility (1 year)
- 48.4%
- Relative volume
- 0.60×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLRX | S&P 500 | Difference | PLRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.8% | -2.4% | −21.4 pts | ||
| 3 months | -24.5% | -1.2% | −23.4 pts | ||
| Year to date | -36.3% | +12.3% | −48.6 pts | ||
| 1 year | -53.4% | +12.4% | −65.9 pts | ||
| 3 years | -94.4% | +78.8% | −173.2 pts | -61.7% | +21.4% |
| 5 years | -95.3% | +75.2% | −170.5 pts | -45.8% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pliant Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Pliant Therapeutics
Pharmaceutical Preparations
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for the treatment of solid tumors and other diseases. The company utilizes a proprietary drug discovery platform built around a library of over 15,000 integrin-binding molecules to generate targeted treatments and cell-specific drug delivery mechanisms. Its lead wholly owned product candidate, PLN-101095, is an oral, small molecule dual inhibitor targeting αvβ8 and αvβ1 integrins designed to sensitize tumors to immunotherapies. Pliant evaluates its therapies for patients with cancers resistant to immune checkpoint inhibitors.
Company profile, executives and historyPliant Therapeutics stock: common questions
What is Pliant Therapeutics's stock price?
PLRX closed at $0.78 on Nov 11, 2026, down 1.03% on the day. Over the past 52 weeks it traded between $0.76 and $1.81.
What is Pliant Therapeutics's market cap?
Pliant Therapeutics was worth $48.15M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PLRX's P/E ratio?
Pliant Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.45), so it has no meaningful P/E ratio.
How much revenue does Pliant Therapeutics make?
Pliant Therapeutics reported revenue of $0 for fiscal 2025.
Does Pliant Therapeutics pay a dividend?
No. Pliant Therapeutics has not paid a cash dividend over the last twelve months.
When does Pliant Therapeutics report earnings next?
Pliant Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has PLRX stock performed over the past year?
Including dividends, PLRX returned -53.4% over the past year, against +12.4% for the S&P 500.
How many PLRX shares are sold short?
5M shares were sold short at the latest FINRA report, 9.06% of the float, or 16.2 days of average trading volume.
Who are Pliant Therapeutics's competitors?
Companies most similar to Pliant Therapeutics by business, industry and size include CNTX, RCUS, CRVS, ZNTL, GRI.
See a number that looks wrong?